Company NGeneBio Co., Ltd.

Equities

A354200

KR7354200008

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Diagnostic & Testing Substances

End-of-day quote Korea S.E. Other stock markets 23:00:00 25/04/2024 BST			5-day change	1st Jan Change
4,275 ^KRW	+1.79%		-32.36%	-23.11%

04-22	NGENEBIO USA Holdings, INC. announced that it expects to receive KRW 3.7395 billion in funding from NGeneBio Co., Ltd.	CI
04-15	J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3 billion.	CI

NGeneBio Co Ltd is a Korea-based company engaged in the manufacture and sale of precision diagnostic products. The Company's main products include BRCAaccuTest products used for hereditary breast and ovarian cancer testing, HEMEaccuTest products that tests the causative genes related to blood cancer such as leukemia, lymphoma, and bone marrow cancer, SOLIDaccuTest products that test the causative genes of solid cancer tissues such as lung cancer, colon cancer and stomach cancer. In addition, the Company manufactures and sells products of HLAaccuTest products that tests tissue-specific antigens used for bone marrow transplantation, ONCOaccuPanel products for precise diagnosis of large-capacity solid cancer, HEREDaccuTest products for precise diagnosis for rare diseases. The Company also provides services such as genetic testing direct to customer(DTC) and personalized healthcare.

KRW in Million	2022	Weight	2023	Weight	Delta
Precision Diagnosis Products 52.7 %	3,492	31.7 %	2,293	52.7 %	-34.32%
DTC 25.2 %	5,978	54.3 %	1,096	25.2 %	-81.66%
Research Service 17.1 %	301	2.7 %	743	17.1 %	+146.99%
Goods 4.5 %	1,227	11.1 %	196	4.5 %	-84.06%
Lease 0.5 %	20	0.2 %	23	0.5 %	+11.76%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	11,018	100.0 %	4,351	100.0 %	-60.51%

Managers	Title	Age	Since
Dae-Chul Choi CEO	Chief Executive Officer	52	-
Kwang-Joong Kim CTO	Chief Tech/Sci/R&D Officer	52	-
Se-Hyuk Yoon PRN	Corporate Officer/Principal	47	-
Hoon-Shik Kim AUD	Comptroller/Controller/Auditor	62	-

Members of the board	Title	Age	Since
Mahn-Soon Hwang BRD	Director/Board Member	54	-
Young-Ho Moon BRD	Director/Board Member	62	-
Dae-Chul Choi CEO	Chief Executive Officer	52	-
Kwang-Joong Kim CTO	Chief Tech/Sci/R&D Officer	52	-
Gi-Won Kang BRD	Director/Board Member	61	-
Jun-Seok Choi BRD	Director/Board Member	52	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	12,889,227	8,454,468 ( 65.59 %)	0	65.59 %

Name	Equities	%	Valuation
GENCURIX INC. 11.64 %	1,500,000	11.64 %	6 M ₩
KT CORPORATION 10.51 %	1,354,545	10.51 %	5 M ₩
Orion Asset Management Co. Ltd. /South Korea/ 5.179 %	667,556	5.179 %	2 M ₩
Dae-Chul Choi 4.022 %	518,400	4.022 %	2 M ₩
Chang-beom Hong 1.844 %	237,650	1.844 %	884 403 ₩
Kwang-Joong Kim 1.251 %	161,250	1.251 %	600 084 ₩
KT Investment, Inc. 1.051 %	135,455	1.051 %	504 089 ₩
Se-Hyuk Yoon 0.6800 %	87,650	0.6800 %	326 185 ₩
Ji-yeon Kim 0.1133 %	14,603	0.1133 %	54 344 ₩

NGeneBio Co., Ltd.

30 Daeryung Post Tower 1-Cha 288 Digital-ro

08390, Seoul

http://www.ngenebio.com

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
NGENEBIO CO., LTD.	-23.11%	40.03M
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances